Pulmonx Corporation (LUNG) Q3 2024 Earnings Call Transcript Summary
Pulmonx Corporation (LUNG) Q3 2024 Earnings Call Transcript Summary
Gross margin maintained at 74%, despite changes in geographic mixThe following is a summary of the Pulmonx Corporation (LUNG) Q3 2024 Earnings Call Transcript:
以下是Pulmonx公司（LUNG）2024年第三季度業績會實錄摘要：
Financial Performance:
金融業績：
Pulmonx reported a total worldwide revenue of $20.4 million for Q3, up 15%
U.S. revenue grew by 17% year-over-year, while international revenue increased by 12%
Gross margin maintained at 74%, despite changes in geographic mix
Reduced net loss to $14.1 million from $14.9 million in the same quarter last year
Pulmonx報告第三季度全球營業收入爲2040萬美元，同比增長15%
美國營業收入同比增長17%，而國際營業收入增長12%
毛利率保持在74%，儘管地理結構發生變化
將淨損失從去年同期的1490萬美元降至1410萬美元
Business Progress:
業務進展：
Implemented strategic commercial pillars leading to 280 active Zephyr Valve accounts across the U.S
Launched LungTraX Platform pilot, a diagnostic tool aimed at streamlining patient workflows and identifying eligible patients
Expanded international operations, particularly through new distributor relationships in China and ongoing European engagements
Advanced clinical trials for AeriSeal system with promising data, supporting future commercial availability
實施戰略性商業支柱，美國境內擁有280個活躍的Zephyr Valve帳戶
推出LungTraX平台試點，這是一個旨在簡化患者工作流程並確定符合條件患者的診斷工具
通過與中國的新經銷商關係和歐洲的持續合作，擴大國際業務
針對具有前景數據的AeriSeal系統展開先進的臨床試驗，支持未來的商業可用性
Opportunities:
機會：
The international revenue growth, particularly with contributions from a new distributor in China, indicates expanding global market presence
Potential growth opportunities from the LungTraX platform once fully deployed in customer centers
尤其是中國的新經銷商的貢獻，國際營業收入增長快速，表明全球市場份額擴大
一旦在客戶中心完全部署，LungTraX平台可能帶來潛在的增長機會
Risks:
風險：
Seasonality impacts observed in Q3, could pose risks if similar patterns affect future quarters
Integration and adoption delays for LungTraX Platform could affect expected benefits and revenue from this technology
觀察到Q3季節性影響，如果類似模式影響未來季度，可能會帶來風險
pulmonx肺部科技平台的整合和採用延遲可能會影響預期的收益和營業收入
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
